MBX Biosciences, Inc. - 8-K Filing
MBX Biosciences reported $440 million in cash and investments as of March 31, 2026, which is expected to fund operations through 2029. The company plans to initiate a Phase 3 trial of once-weekly canvuparatide in Q3 2026 and will present Phase 2 results at ENDO 2026 in June. R&D expenses were $18.5 million for the first quarter, down from $22.4 million in the same period in 2025. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $MBX